Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
2017-004645-24Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and Proteinase 3 ANCA-associated vasculitis (PR3-AAV) comparing Belimumab plus rituximab/standard treatment with Placebo plus rituximab/standard treatment (2 arms). Primary endpoint: Time to PR3 ANCA negativity. Status: unknown.
02
Drugs
belimumabrituximab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)Proteinase 3 ANCA-associated vasculitis (PR3-AAV)
Beyond the preview
Go deeper on 2017-004645-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004645-24.